haidut

Member
Joined
Mar 18, 2013
Messages
17,533
Location
USA / Europe
Yet another study demonstrating that many of the so-called chronic, degenerative and above all "mysterious" conditions often have quite a simple cause and, potentially, treatment. There is no need for mutated genes or complex interactions of genes with environment that nobody can decipher. Chronic stress leads to metabolic and endocrine changes that alone are sufficient to cause virtually all "named" pathologies we have on the books. Just as importantly, endogenous chemicals that have been declared "evil" for more than a century, now turn out to be among the most protective substances available to medicine. Case in point - the study demonstrated that all it takes for PD to develop in males is a sudden drop in androgen levels. While the study mentions both testosterone (T) and DHT as key players, the treatment regimen in this study for reversing PD used DHT instead of T. Yes, that same "evil" DHT that we have been told causes prostate cancer, baldness, obesity, PCOS, osteoporosis, etc. /s

All it took to reverse the symptoms of PD in these castrated rodents was DHT supplementation with HED of ~2mg/kg daily, for 30 days. This dose of DHT is high, but in extreme (and sudden) cases such as castration much higher doses of an androgen may be needed to reverse severe brain pathologies. Other rodent studies have shown that DHT at a HED of 5mg-10mg daily also has robust neuroprotective effects. Interestingly, the drop in androgen levels caused a massive increase in nitric oxide (NO) synthesis. This elevation in NO resulted in destruction of dopamine-producing neurons, as well as a drop in the brain-anabolic factor GDNF. DHT administration reversed all of these pathological changes. Speaking of androgen-depleting events - physical or chemical castration is not the only possible cause. Chronic stress, emotional trauma, radiation exposure (X-rays anyone?), endocrine disruptors, infectious disease, endotoxin, SSRI drugs, PPI drugs, statins, PUFA, etc all count as "castration" events that can potentially cause such PD-inducing drop in androgen levels.

Btw, the reason the study authors used DHT instead of T was that they were concerned about T aromatizing easily to estrogen, considering the negative effects estrogen has on brain pathologies like PD in males. In fact, the role of estrogen in PD pathology is acknowledged to the point that aromatase inhibitors are proposed as promising candidates for treating PD.

Potential repositioning of exemestane as a neuroprotective agent for Parkinson's disease. - PubMed - NCBI

Well, if androgen drop causes PD, androgen administration reverses it, and estrogen administration worsens it then the only conclusion is that DHT is the main protective factor here. T, aside from its conversion into estrogen, has only one other pathway it can go towards - conversion into DHT. Actually, it can convert back into androstenedione but that pathway is minor and also leads to estrogen. Finally, DHT lowers estrogen but T does not (it even increases it). So, it is fair to say that loss/decline of potent androgenic steroids can cause PD and supplementation with the most potent endogenous non-aromatizabe androgen (DHT) can reverse it. Considering the causative role elevated NO and lower dopamine (and as such higher prolactin) play in prostate cancer, the whole approach with chemical castration starts to look even more absurd. If anything, this study suggests that DHT should be used to treat prostate cancer :):

Castration Induces Parkinson Disease Pathologies in Young Male Mice via Inducible Nitric-oxide Synthase

"...To find out whether the observed pathological changes are due to castration-related loss of male sex hormone, we performed this experiment. However, testosterone may be converted into estrogen by aromatase. Therefore, to avoid the complexity, castrated male mice received DHT pellets (30-day release), which were implanted subcutaneously in the scapular area of the neck of castrated male mice on the day of castration (Fig. 8A). It is interesting to see that DHT supplementation protected nigral TH (Fig. 8, B and C) and preserved striatal DA (Fig. 8D) in 4–5-week-old castrated male mice. Accordingly, DHT supplementation also improved rotarod performance (Fig. 8E), horizontal activity (Fig. 8F), total distance (Fig. 8G), movement time (Fig. 8H), number of movement (Fig. 8I), and stereotypy (Fig. 8J)."

"...On the other hand, NO has also been implicated in several CNS disorders, including inflammatory, infectious, traumatic, and degenerative diseases (18, 3638). There is considerable evidence for the transcriptional induction of iNOS (the high output isoform of NOS) in the CNS that is associated with degenerative brain injury (18, 35, 37, 38). NO is potentially toxic to neurons and oligodendrocytes that may mediate toxicity through the formation of iron-NO complexes of iron-containing enzyme systems (39), oxidation of protein sulfhydryl groups (40), nitration of proteins, and nitrosylation of nucleic acids and DNA strand breaks (41). Here, we have described a new mechanism by which iNOS-derived NO may couple nigrostriatal degeneration (summarized in Fig. 12I). Whereas castration increased the expression of iNOS in the nigra, the level of GDNF went down drastically in the nigra after castration. "

Sudden decline in testosterone may cause Parkinson's disease symptoms in men

"..."While scientists use different toxins and a number of complex genetic approaches to model Parkinson's disease in mice, we have found that the sudden drop in the levels of testosterone following castration is sufficient to cause persistent Parkinson's like pathology and symptoms in male mice," said Dr. Kalipada Pahan, lead author of the study and the Floyd A. Davis endowed professor of neurology at Rush. "We found that the supplementation of testosterone in the form of 5-alpha dihydrotestosterone (DHT) pellets reverses Parkinson's pathology in male mice." "In men, testosterone levels are intimately coupled to many disease processes," said Pahan. Typically, in healthy males, testosterone level is the maximum in the mid-30s, which then drop about one percent each year. However, testosterone levels may dip drastically due to stress or sudden turn of other life events, which may make somebody more vulnerable to Parkinson's disease. "Therefore, preservation of testosterone in males may be an important step to become resistant to Parkinson's disease," said Pahan. Understanding how the disease works is important to developing effective drugs that protect the brain and stop the progression of Parkinson's disease. Nitric oxide is an important molecule for our brain and the body. "However, when nitric oxide is produced within the brain in excess by a protein called inducible nitric oxide synthase, neurons start dying," said Pahan."
 

Broken man

Member
Joined
Sep 11, 2016
Messages
1,459
Good one, can I ask you, why I cant use Keto dht without pregnenolone on my rat? Thank you.
 

milk_lover

Member
Joined
Aug 15, 2015
Messages
1,769
It’s sadly banned in my country. What comes the closest to DHT in your opinion?
 

Tarmander

Member
Joined
Apr 30, 2015
Messages
3,508
The question is why would androgens drop so suddenly in a human?

makes sense that lower T and PD would tie together because of T and dopamines buddy buddy relationship. I wonder though if overtime the dopamine system would adapt to the lower T levels. Women obviously don’t have high T (other then college professors) and aren’t devastated by high PD levels.
 

Mito

Member
Joined
Dec 10, 2016
Messages
1,853
Case in point - the study demonstrated that all it takes for PD to develop in males is a sudden drop in androgen levels.
Why don’t men treated for prostate cancer develop PD?
 
Joined
Dec 18, 2018
Messages
2,207
Didnt read those studies,high probability i wont read them later.
But others can have insight,

"Why don’t men treated for prostate cancer develop PD?"

"Good question , I was looking it would totally make sense..."

maybe they do.

Search terms in google scholar:
https://scholar.google.de/scholar?h...state+cancer+develop+parkinsons+disease&btnG=



Association between Parkinson's disease and risk of prostate cancer in different populations: An updated meta-analysis.
Chen C, et al. Sci Rep. 2017.
Show full citation
Abstract

Recently, growing evidence has revealed a significant association between Parkinson's disease (PD) and cancer. However, controversy still exists concerning the association between PD and prostate cancer. A comprehensive article search for relevant published studies was performed using the online databases PubMed, Web of Science and Embase up to January 1, 2017. The pooled risk ratios (RRs) and their 95% confidence intervals (CIs) were calculated using the method of inverse variance with a random-effects model. Fifteen studies comprising 346,153 PD patients were included in this study. The results of the present study showed that PD was significantly associated with a decreased risk of prostate cancer in the Western population (RR: 0.83, 95% CI: 0.72-0.95, P < 0.01), while an increased risk of prostate cancer was shown in the Asian population (RR: 1.80, 95% CI: 1.52-2.13, P < 0.001). In the subgroup analysis, the reduced risk of prostate cancer in PD patients from Western populations was consistent regardless of study design or study quality. In conclusion, PD was significantly associated with a reduced risk of prostate cancer in the Western population. The relationship between those conditions in the Asian population needs to be confirmed by future studies.







Parkinson's disease and cancer risk: a systematic review and meta-analysis.
Review article
Bajaj A, et al. Cancer Causes Control. 2010.
Show full citation
Abstract

OBJECTIVE: To appraise the existing literature on cancer risk among patients with Parkinson's disease (PD), determine the overall cancer risk ratio among patients with PD, explore reasons for variations in study results, and assess the potential for publication bias.

METHODS: Studies reporting cancer risk in patients with PD were identified by searching electronic databases through 18 November 2009 using the terms PARKINSON DISEASE, NEOPLASM, and CANCER. Reviewers individually performed data extraction and scored each study using a quality assessment instrument. Cancer risk in all patients with PD was calculated overall, and after excluding melanoma and other skin cancers. We tested for heterogeneity and publication bias, and stratified for gender, smoking-related versus non-smoking-related cancers, and study quality. We pooled effect sizes using fixed-effects and random-effects models.

RESULTS: We included 29 studies in the overall analysis for a total of 107,598 patients with PD. Compared to controls, the aggregate risk for cancer in patients with PD was 0.73 (95% confidence interval [CI], 0.63-0.83), and after excluding skin tumors, 0.69 (95% CI, 0.62-0.78). These risks varied by gender (males, RR = 0.71, 95% CI, 0.57-0.88; females, RR = 0.82; 95% CI, 0.68-0.98). After strictly excluding skin tumors, both smoking-related (RR = 0.61; 95% CI, 0.58-0.65) and non-smoking-related cancer rates (RR = 0.76; 95% CI, 0.65-0.89) were significantly lower among patients with PD .

CONCLUSIONS: Studies on cancer risk among patients with PD collectively show significantly reduced cancer risk ratios. Further research to explain the biological mechanisms, particularly for the association with non-smoking-related cancers, appears warranted.
 

Mauritio

Member
Joined
Feb 26, 2018
Messages
2,264
Didnt read those studies,high probability i wont read them later.
But others can have insight,

"Why don’t men treated for prostate cancer develop PD?"

"Good question , I was looking it would totally make sense..."

maybe they do.

Search terms in google scholar:
https://scholar.google.de/scholar?hl=de&as_sdt=0,5&q=prostate+cancer+develop+parkinsons+disease&btnG=



Association between Parkinson's disease and risk of prostate cancer in different populations: An updated meta-analysis.
Chen C, et al. Sci Rep. 2017.
Show full citation
Abstract

Recently, growing evidence has revealed a significant association between Parkinson's disease (PD) and cancer. However, controversy still exists concerning the association between PD and prostate cancer. A comprehensive article search for relevant published studies was performed using the online databases PubMed, Web of Science and Embase up to January 1, 2017. The pooled risk ratios (RRs) and their 95% confidence intervals (CIs) were calculated using the method of inverse variance with a random-effects model. Fifteen studies comprising 346,153 PD patients were included in this study. The results of the present study showed that PD was significantly associated with a decreased risk of prostate cancer in the Western population (RR: 0.83, 95% CI: 0.72-0.95, P < 0.01), while an increased risk of prostate cancer was shown in the Asian population (RR: 1.80, 95% CI: 1.52-2.13, P < 0.001). In the subgroup analysis, the reduced risk of prostate cancer in PD patients from Western populations was consistent regardless of study design or study quality. In conclusion, PD was significantly associated with a reduced risk of prostate cancer in the Western population. The relationship between those conditions in the Asian population needs to be confirmed by future studies.







Parkinson's disease and cancer risk: a systematic review and meta-analysis.
Review article
Bajaj A, et al. Cancer Causes Control. 2010.
Show full citation
Abstract

OBJECTIVE: To appraise the existing literature on cancer risk among patients with Parkinson's disease (PD), determine the overall cancer risk ratio among patients with PD, explore reasons for variations in study results, and assess the potential for publication bias.

METHODS: Studies reporting cancer risk in patients with PD were identified by searching electronic databases through 18 November 2009 using the terms PARKINSON DISEASE, NEOPLASM, and CANCER. Reviewers individually performed data extraction and scored each study using a quality assessment instrument. Cancer risk in all patients with PD was calculated overall, and after excluding melanoma and other skin cancers. We tested for heterogeneity and publication bias, and stratified for gender, smoking-related versus non-smoking-related cancers, and study quality. We pooled effect sizes using fixed-effects and random-effects models.

RESULTS: We included 29 studies in the overall analysis for a total of 107,598 patients with PD. Compared to controls, the aggregate risk for cancer in patients with PD was 0.73 (95% confidence interval [CI], 0.63-0.83), and after excluding skin tumors, 0.69 (95% CI, 0.62-0.78). These risks varied by gender (males, RR = 0.71, 95% CI, 0.57-0.88; females, RR = 0.82; 95% CI, 0.68-0.98). After strictly excluding skin tumors, both smoking-related (RR = 0.61; 95% CI, 0.58-0.65) and non-smoking-related cancer rates (RR = 0.76; 95% CI, 0.65-0.89) were significantly lower among patients with PD .

CONCLUSIONS: Studies on cancer risk among patients with PD collectively show significantly reduced cancer risk ratios. Further research to explain the biological mechanisms, particularly for the association with non-smoking-related cancers, appears warranted.

I don't get your point, you sound like you say it is the case that there is a correlation between prostate cancer treatment and Parkinson's but the study says the opposite.
And our point was, there might be a chronological order : first prostate cancer (and treatment) , then cancer. And not the other way around.
Since prostate cancer treatment causes a sudden drop in androgen and this might lead to Parkinson's as per haiduts study.
 

Cameron

Member
Joined
Jul 14, 2018
Messages
738
Location
Tennessee
Are there any countries where dht is sold as a research chemical and easy to obtain? I’m wondering if Canada is easy to obtain pure dht for research as possessing steroids is not illegal only selling them is. Finding a pre made non toxic solution seems difficult to find as well.
 

Cameron

Member
Joined
Jul 14, 2018
Messages
738
Location
Tennessee
What is the theory on dht supplementation in humans and suppression. I’ve seen both the theory dht in any dose with suppression on hpta and testosterone. I’ve also seen the opposite that dht will have positive effect on its own production and positive effect on t and e and therefore safe to use in supplementation. Can we suspect dht is the safe form of hrt in men? Is dht actually less suppressing to the entire endocrine system? Oral dht or dht pellets for best dht type hrt in men?
 
Joined
Dec 18, 2018
Messages
2,207
I don't get your point, you sound like you say it is the case that there is a correlation between prostate cancer treatment and Parkinson's but the study says the opposite.
And our point was, there might be a chronological order : first prostate cancer (and treatment) , then cancer. And not the other way around.
Since prostate cancer treatment causes a sudden drop in androgen and this might lead to Parkinson's as per haiduts study.


True.
I dont have a point in this matter yet.
i wanted to post something to chew on for members.
 
Joined
Dec 18, 2018
Messages
2,207
What is the theory on dht supplementation in humans and suppression. I’ve seen both the theory dht in any dose with suppression on hpta and testosterone. I’ve also seen the opposite that dht will have positive effect on its own production and positive effect on t and e and therefore safe to use in supplementation. Can we suspect dht is the safe form of hrt in men? Is dht actually less suppressing to the entire endocrine system? Oral dht or dht pellets for best dht type hrt in men?


I would also like to hear someone who have ideas about suppression or knowledge of the course and consequences of such side effects.
 

Mufasa

Member
Joined
Jun 10, 2016
Messages
538
@haidut Do you think that the same kind of effects can be accomplished with androsterone? (for my research with parkinson rats)
 
Joined
Dec 18, 2018
Messages
2,207

J Biol Chem. 2013 Jul 19; 288(29): 20843–20855.
Published online 2013 Jun 6. doi: 10.1074/jbc.M112.443556
PMCID: PMC3774356
PMID: 23744073
Castration Induces Parkinson Disease Pathologies in Young Male Mice via Inducible Nitric-oxide Synthase*
Saurabh Khasnavis, Anamitra Ghosh, Avik Roy, and Kalipada Pahan1
Author information Article notes Copyright and License information Disclaimer
This article has been cited by other articles in PMC.
Go to:
Abstract
Although Parkinson disease (PD) is a progressive neurodegenerative disorder, available animal models do not exhibit irreversible neurodegeneration, and this is a major obstacle in finding out an effective drug against this disease. Here we delineate a new irreversible model to study PD pathogenesis. The model is based on simple castration of young male mice. Levels of inducible nitric-oxide synthase (iNOS), glial markers (glial fibrillary acidic protein and CD11b), and α-synuclein were higher in nigra of castrated male mice than normal male mice. On the other hand, after castration, the level of glial-derived neurotrophic factor (GDNF) markedly decreased in the nigra of male mice. Accordingly, castration also induced the loss of tyrosine hydroxylase-positive neurons in the nigra and decrease in tyrosine hydroxylase-positive fibers and neurotransmitters in the striatum. Reversal of nigrostriatal pathologies in castrated male mice by subcutaneous implantation of 5α-dihydrotestosterone pellets validates an important role of male sex hormone in castration-induced nigrostriatal pathology. Interestingly, castration was unable to cause glial activation, decrease nigral GDNF, augment the death of nigral dopaminergic neurons, induce the loss of striatal fibers, and impair neurotransmitters in iNOS−/− male mice. Furthermore, we demonstrate that iNOS-derived NO is responsible for decreased expression of GDNF in activated astrocytes. Together, our results suggest that castration induces nigrostriatal pathologies via iNOS-mediated decrease in GDNF. These results are important because castrated young male mice may be used as a simple, toxin-free, and nontransgenic animal model to study PD-related nigrostriatal pathologies, paving the way for easy drug screening against PD.

Keywords: Microglia, Neurodegeneration, Neuroinflammation, Nitric-oxide Synthase, Parkinson Disease, Castration
Go to:
Introduction
Parkinson disease (PD)2 is a progressive neurodegenerative disease with unclear etiology. PD may appear at any age, but it is uncommon in people younger than 30. The usual age of onset is between 50 and 70. The actual cause of PD is not known. It is believed that a complex interaction between environmental and genetic factors plays the major role in causing the disease (13). PD is characterized by a severe shortage of dopamine (DA), an important neurotransmitter. It is this deficiency that causes the symptoms of PD. The deficiency of DA is caused by the gradual loss of dopaminergic neurons that being present in the substantia nigra pars compacta (SNpc) synthesize DA from tyrosine via tyrosine hydroxylase. Once patients are diagnosed with PD, there is no drug available to halt its progression.

One of the major roadblocks for discovering drugs against PD is the unavailability of a true chronic persistent animal model for PD (3). One neurotoxin, MPTP, has been being used since the 1980s to model PD. However, for most MPTP models, the loss of dopamine is rapid and reversible. The extent of nigrostriatal damage also decreases in chronic MPTP models with time (4, 5). Because familial PD is associated with mutations of different genes, such as α-synuclein, parkin, PINK1, and DJ1 (6), efforts have been made to generate genetically engineered mice that express these mutated genes (7). Transgenic animals that overexpress α-syn or mutated human α-syn A53T have been used to study the role of this protein in dopaminergic degeneration. Although some transgenic mice expressing mutated α-syn display motor neuron pathology, these mice do not exhibit death of dopaminergic neurons (8). Many mutations in the gene encoding parkin cause a significant portion of early onset familial PD (8). Most of these mutations likely cause a loss of function in parkin, an E3 ubiquitin ligase, probably leading to proteasomal dysfunction. However, mice with mutated parkin exhibit progressive sensorimotor dysfunction without any DA cell loss (9). DJ1 mutations cause decreased resistance to oxidative stress in cells, flies, and mice (9). DJ1 KO mice, however, have little phenotype and do not develop DA cell loss. Furthermore, almost all of these transgenic mice exhibit any pathology at a much later age (>10 months), making studies more expensive and difficult.

Therefore, developing a chronic irreversible animal model to study the pathogenesis of PD is of paramount importance, and here we describe a simple, toxin-free and nontransgenic mouse model for PD. Castration induces nigral glial activation, decrease in nigral GDNF, demise of tyrosine hydroxylase (TH)-positive neurons in the nigra, loss of TH fibers and neurotransmitters in the striatum, and impairment of locomotor activities in young male mice. However, castration is unable to induce these nigrostriatal pathologies in male inducible nitric-oxide synthase (iNOS)-null mice. Furthermore, we demonstrate that the expression of GDNF is suppressed by NO. Taken together, these results suggest that castration induces PD-like pathologies in male mice via iNOS-mediated suppression of GDNF.

Go to:
MATERIALS AND METHODS
Reagents
Fetal bovine serum (FBS), Hanks' balanced salt solution, trypsin, and DMEM/F-12 were from Mediatech. 5α-Dihydrotestosterone (DHT) 30-day release pellets and placebo pellets were obtained from Innovative Research of America (Sarasota, FL). Animal maintenance and experiments were in accordance with National Institute of Health guidelines and were approved by the Institutional Animal Care and Use committee (IACUC) of the Rush University of Medical Center. Primary antibodies, their sources, and concentrations used are listed in Table 1. Alexa Fluor antibodies used in immunostaining were obtained from Jackson ImmunoResearch, and IR dye-labeled reagents used for immunoblotting were from Li-Cor Biosciences.

TABLE 1
Antibodies, sources, applications, and dilutions used

Antibody Manufacturer Catalog no. Host Applicationa Dilution/amount
GDNF Abcam ab18956 Rabbit WB/IF 1:1000
GDNF Millipore AB5252P Ship IHC 1:500
β-Actin Abcam ab6276 Mouse WB 1:6000
iNOS BD Biosciences 610432 Mouse WB/IHC 1:1000
IL-1β Santa Cruz sc7884 Rabbit WB 1:200
GFAP Dako Z0334 Rabbit ICC/IF/WB 1:1500
GFAP Santa Cruz sc6171 Goat ICC/IF 1:200
Iba-1 Abcam ab5076 Goat IHC/WB 1:500
CD11b Cedarlane Scl8941A Rabbit ICC 1:200
TH Calbiochem 657012 Rabbit IHC/WB 1:1000
a WB, Western blotting; IF, immunofluorescence; IHC, immunohistochemistry; ICC, immunocytochemistry.

Isolation of Primary Mouse Astroglia
Astroglia were isolated from brains of 7–9-day-old mouse pups as we described before (1012).

Castration of Male C57BL/6 Mice
Mice (4 weeks old) were anesthetized, shaved, and prepared with providone and ethanol. An incision was made in the scrotum, followed by an incision in the tunica of the first testicle. The testis, vas deferens, and the attached testicular fat pad were exteriorized. A hemostat was used to clamp the blood vessels, and a figure-of-8 knot was tied above. The testis, vas deferens, and fatty tissue were severed just below the hemostat. The tunica on the contralateral side was similarly penetrated and the procedure repeated. The scrotum incision was closed using wound clips. Sham animals were anesthetized, shaved, and prepared with providone and ethanol. An incision was made in the scrotum. After that, the scrotum incision was closed using would clips. Postoperative care including analgesic administration remained the same as castrated mice.

Assessment of Serum Testosterone Levels
Testosterone was measured from the serum samples using Testosterone EIA kit from Enzo Life Sciences, following the manufacturer's instructions. Samples were diluted (1:20) and run in duplicate. The detection range of this kit is 7.81–2,000 pg/ml.

Implantation of DHT Pellets
DHT as well as placebo pellets were implanted subcutaneously in the scapular area of the neck of castrated male mice using a trochar.

Semiquantitative RT-PCR Analysis
To remove any contaminating genomic DNA, total RNA was digested with DNase. Semiquantitative RT-PCR was carried out as described earlier (1012) using a RT-PCR kit from Clontech. Briefly, 1 μg of total RNA was reverse-transcribed using oligo(dT)12–18 as primer and MMLV reverse transcriptase (Clontech). The resulting cDNA was appropriately diluted, and diluted cDNA was amplified. Amplified products were electrophoresed on a 1.8% agarose gels and visualized by ethidium bromide staining. Primers were: iNOS sense, 5′-CCCTTCCGAAGTTTCTGGCAGCAGC-3′ and antisense, 5′-GGCTGTCAGAGCCTCGTGGCTTTGG-3′; IL-1β sense, 5′-CTCCATGAGCTTTGTACAAGG-3′ and antisense, 5′-TGCTGATGTACCAGTTGGGG-3′; TNF-α sense, 5′-TTCTGTCTACTGAACTTCGGGGTGATCGGTCC-3′ and antisense, 5′-GTATGAGATAGCAAATCGGCTGACGGTGTGGG-3′; CD11b sense, 5′-GTGAGGATTCCTACGGGACCCAGGT-3′ and antisense, 5′-GGCGTACTTCACAGGCAGCTCCAAC-3′; GFAP sense, 5′- GGCGCTCAATGCTGGCTTCA-3′ and antisense, 5′- TCTGCCTCCAGCCTCAGGTT-3′; GAPDH sense, 5′-GGTGAAGGTCGGTGTGAACG-3′ and antisense, 5′-TTGGCTCCACCCTTCAAGTG-3′.

Real-time PCR Analysis
PCR analysis was performed using the ABI-Prism7700 sequence detection system (Applied Biosystems) as described earlier (1012). The mRNA expressions of respective genes were normalized to the level of GAPDH mRNA. Data were processed by the ABI Sequence Detection System 1.6 software and assessed by analysis of variance.

Immunohistochemistry and Quantitative Morphology
Mice were perfused and their brains fixed, embedded, and processed for TH staining as described previously (1315). Total numbers of TH-stained neurons in the SNpc were counted stereologically with STEREO INVESTIGATOR software (MicroBrightfield, Williston, VT) by using optical fractionators (1316). Quantitation of striatal TH immunostaining was performed as described (13, 14, 17). Optical density measurements were obtained by digital image analysis (Scion, Frederick, MD). Striatal TH optical density reflected dopaminergic fiber innervation. For immunofluorescence staining on fresh frozen sections, rat anti-mouse CD11b (1:100), goat anti-mouse GFAP (1:100), and rabbit anti-mouse iNOS (1:250) were used. The samples were mounted and observed under a Bio-Rad MRC1024ES confocal laser scanning microscope.

HPLC Analysis for Measurement of Striatal DA and Its Metabolite Levels
Striatal levels of DA, 3,4-dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA) were quantified as described earlier (1317). Briefly, mice were sacrificed by cervical dislocation, and their striata were collected and immediately frozen in dry ice and stored at −80 ºC until analysis. On the day of the analysis, tissues were sonicated in 0.2 m perchloric acid containing isoproterenol, and the resulting homogenates were centrifuged at 20,000 × g for 15 min at 4 ºC. After pH adjustment and filtration, 10 μl of supernatant was injected onto an Eicompak SC-3ODS column (Complete Stand-Alone HPLC-ECD System EiCOMHTEC-500 from JM Science Inc., Grand Island, NY) and analyzed following the manufacturer's protocol.

Behavioral Analysis
Two types of behavioral experiments were conducted 30 days after castration. This included an open field experiment for locomotor activity and rotarod experiment for feet movement as described earlier (1315, 17). The feet movement of the mice was observed on rotarod that was set to accelerate from 4 to 40 rpm over a 5-min period. Locomotor activity was monitored in Digiscan Monitor (Omnitech Electronics, Inc., Columbus, OH). This Digiscan Monitor records stereotypy and rearing, behaviors that are directly controlled by the striatum, as well as other basic locomotion parameters, such as horizontal activity, total distance traveled, number of movements, movement time, rest time, mean distance, mean time, and center time. Mice were placed inside the Digiscan Infra-red Activity Monitor for 10 min daily for 2 consecutive days for acclimatization followed by test on the 3rd day. Briefly, animals were removed directly from their cages and gently placed nose first into a specified corner of the open-field apparatus and after release, data acquisition began every 5-min interval. DIGISCAN software was used to analyze and store horizontal and vertical activity data, which were monitored automatically by infrared beams.

Statistics
All values are expressed as means ± S.E. Differences among means were assessed by one-way analysis of variance. In other cases, Student's t test was used to compare outcome between two groups (e.g. sham versus castrated, WT versus iNOS-null).

Go to:
RESULTS
Castration Up-regulates Glial Activation in the SNpc
In an effort to explore a toxin-free nontransgenic model to study PD-related nigrostriatal pathologies, we castrated young 4–5-week-old male C57BL/6 mice. Because glial activation plays an important role in the pathogenesis of PD (13, 1719), at first we monitored the status of glial activation in the SNpc of castrated mice. Glial activation is characterized by increase in glial marker proteins such as GFAP for astrocytes and CD11b for microglia. Therefore, we examined the effect of simple castration on the expression of GFAP and CD11b in the SNpc. One month after castration, we observed a marked increase in the mRNA expression of GFAP and CD11b in the SNpc compared with age-matched sham male mice (Fig. 1, A and B). In addition to CD11b, microglia are also known to immunoreact with Iba1. Western blotting and immunofluorescence analysis also reveal marked increase in the expression of GFAP (Fig. 1, C, D, and F) and Iba-1 (Fig. 1, C, E, and G) proteins in the SNpc of castrated mice.

Open in a separate window
FIGURE 1.
Castration increases gliosis in the SNpc of male mice. A and B, male C57BL/6 mice (4–5 weeks old) were castrated, and 30 days later, the mRNA expression of GFAP and CD11b was measured in the nigra by semiquantitative RT-PCR (A) and real-time PCR (B). C, protein levels of GFAP and Iba-1 were monitored in the nigra by Western blotting. D and E, actin was run as loading control. Bands were scanned and are expressed relative to sham control (D, GFAP; E, Iba-1). Results represent mean ± S.E. (error bars) of six mice per group. a, p < 0.001 versus sham-control. F and G, nigral sections were also immunostained for GFAP (F) and Iba-1 (G). DAPI was used to visualize nuclei. Results represent analysis of two sections of each of six mice per group.

Glial activation is always associated with the up-regulation of various proinflammatory molecules, including IL-1β, TNF-α and iNOS (17, 20). Accordingly, we observed increased mRNA expression of iNOS, IL-1β, and TNF-α in the nigra of castrated mice compared with sham mice (Fig. 2, A and B). Western blot analysis of nigral homogenates also revealed marked increase in iNOS and IL-1β proteins in the nigra of castrated male mice compared with sham mice (Fig. 2, C–E). As evident from immunofluorescence analysis, increased iNOS co-localized to either GFAP-positive astroglia (Fig. 2F) or CD11b-positive microglia (Fig. 2G) in the SNpc of castrated mice. α-Synuclein accumulation is another important feature of PD. Interestingly, castration also increased the level of α-syn in the SNpc of male mice as compared with normal male mice (Fig. 2H).

Open in a separate window
FIGURE 2.
Castration increases the level of proinflammatory molecules and α-syn in the SNpc of male mice. A and B, male C57BL/6 mice (4–5 weeks old) were castrated, and 30 days later, the mRNA expression of iNOS, IL-1β, and TNF-α was measured by semiquantitative RT-PCR (A) and real-time PCR (B). C, protein levels of iNOS and IL-1β were monitored in the nigra by Western blotting. D and E, actin was run as loading control. Bands were scanned and expressed as relative to sham control (D, iNOS; E, IL-1β). Results are mean ± S.E. (error bars) of six mice per group. a, p < 0.001 versus sham-control. F and G, nigral sections were also double-immunolabeled for either GFAP and iNOS (F) or CD11b and iNOS (G). DAPI was used to visualize nucleus. H, nigral sections were immunostained with mouse anti-α-syn and visualized using 3,3′-diaminobenzidine staining. Nissl (0.1% Cresyl Violet solution) was used to visualize neurons. Results represent analysis of two sections, each of six mice per group.

Castration Induces the Loss of Dopaminergic Neurons in the Nigra and TH-positive Fibers in the Striatum and Decreases Striatal Neurotransmitters in Male Mice
Male C57BL/6 mice (4–5 weeks old) were castrated, and 1 month after castration, mice were sacrificed and nigral homogenates were immunoblotted with TH. As evident from Fig. 3, A and B, the expression of TH protein markedly decreased in the nigra of castrated male mice compared with sham mice. To further confirm this finding, brains of castrated and sham mice were fixed, embedded, and processed for TH staining. Total numbers of TH-stained neurons in the SNpc were counted stereologically with STEREO INVESTIGATOR software. Only castration was sufficient to induce the loss of TH-positive neurons on the nigra (Fig. 3, C and E) and the decrease in TH fibers in the striatum (Fig. 3, D and F). Because the levels of DA and its metabolites DOPAC and HVA decrease in the striatum of PD patients, we examined whether castration alone was capable of decreasing these neurotransmitters in male mice. As evident from Fig. 3G, castration significantly decreased the levels of DA, DOPAC, and HVA in the striatum of male C57BL/6 mice. Next, we examined whether this castration-induced decrease in striatal DA was confined to only C57BL/6 background. Decrease in striatal DA in castrated male SJL/J mice compared with sham control (Fig. 3H) suggests that castration-mediated loss of DA is not a strain-specific effect.

Open in a separate window
FIGURE 3.
Castration leads to the loss of dopaminergic neurons in the SNpc of male mice. A, male C57BL/6 mice (4–5 weeks old) were castrated, and 30 days later, nigral homogenates were immunoblotted for TH. Actin was run as loading control. B, bands were scanned and expressed as relative to sham control. Results are mean ± S.E. (error bars) of six mice per group. a, p < 0.001 versus sham-control. C–G, nigral (C) and striatal (D) sections were immunolabeled for TH followed by counting of TH-positive neurons in the SNpc (E), quantification of TH-positive fibers in the striatum (F), and assay of DA, DOPAC, and HVA in the striatum (G). H, male SJL/J mice were also castrated, and 30 days later, DA was quantified in the striatum. Data are means ± S.E. of six mice per group. a, p < 0.0001 versus sham control; b, p < 0.05 versus sham control.

To further prove that this unexpected result is not an artifact of our surgical procedure, we obtained sham and castrated young male mice from Harlan Laboratories (Indianapolis, IN). Mice were castrated at the age of 4–5 weeks and shipped to us 1 week after castration. We also observed marked decrease in striatal DA in all castrated male mice (n = 10) 30 days after castration compared with sham control (data not shown). The incidence of striatal DA loss was 100%.

To understand whether the effect of castration is specific for nigra or other parts of the brain are also affected, 30 days after castration, hippocampal and cortical sections were immunolabeled for NeuN. Interestingly, castration did not decrease the NeuN immunoreactivity in different parts of the hippocampus (Fig. 4, A and B). Similarly, castration also had no effect on NeuN immunostaining in the cortex (Fig. 4C), suggesting the specificity of the effect.

Open in a separate window
FIGURE 4.
Castration does not lead to the loss of hippocampal and cortical neurons. Male C57BL/6 mice (4–5 weeks old) were castrated, 30 days later, hippocampal and cortical sections were immunolabeled for NeuN using 3,3′-diaminobenzidine protocol (anti-NeuN antibody, dilution of 1:500; Millipore). A, hippocampus; B, magnified images of CA3 and DG regions of the hippocampus; C, cortex. Results represent analysis of two sections of each of six mice per group.

Effect of Castration on Locomotor Activities
Next, to examine whether castration caused not only structural and neurotransmitter damage but also functional deficits, we monitored locomotor activities. On the day of testing, mice were recorded twice at an interval of 2 h. Similar to MPTP intoxication, castration alone decreased rotarod performance (Fig. 5A), horizontal activity (Fig. 5B), total distance (Fig. 5C), number of movements (Fig. 5D), movement time (Fig. 5E), rearing (Fig. 5F), stereotypy counts (Fig. 5G), and stereotypy time (Fig. 5H).

Open in a separate window
FIGURE 5.
Castration leads to impairment of locomotor activities in male mice. Male C57BL/6 mice (4–5 weeks old) were castrated, and 30 days later they were tested for motor functions (A, rotarod; B, horizontal activity; C, total distance; D, number of movements; E, movement time; F, rearing; G, stereotypy counts; H, stereotypy time). Data are means ± S.E. (error bars) of six mice per group. a, p < 0.01; b, p < 0.05 versus sham control.

Do Castration-induced Nigrostriatal Pathologies Persist?
PD is both chronic and progressive. Although the MPTP mouse model, the most widely used animal model of PD, is a good one for initial drug screening and investigating the mode of action of a drug, a potential limitation of this model is that its effects are spontaneously reversed over time. Therefore, we examined whether the effects of castration on the nigrostriatum also reversed over time. Seven, 15, 30, 60, and 120 days after castration, mice were sacrificed, and their nigra and striata were collected. Nigra were used for monitoring the mRNA expression of iNOS, CD11b, and GFAP by real-time PCR, and the level of DA was measured in striata by HPLC (Fig. 6A). Within 7 days of castration, we observed significant increase in the expression of iNOS (Fig. 6B), GFAP (Fig. 6C), and CD11b (Fig. 6D), which subsequently increased and became maximum 30 days after castration (Fig. 6, B–D). Interestingly, castration-mediated expression of iNOS, GFAP, and CD11b persisted until the duration (120 days) of the study (Fig. 6, B–D). Although we found glial activation on 7 days after castration, striatal loss of DA was not significant at that time point (Fig. 6E). However, the DA level significantly decreased from 15 days onward and even 120 days after castration, we found no improvement in striatal DA level in castrated male mice compared with age-matched sham male mice (Fig. 6E). These results suggest that castration induces persistent glial activation and stable loss of striatal DA in male mice.

Open in a separate window
FIGURE 6.
Castration induces persistent glial activation and stable loss of striatal dopamine in male mice. Male C57BL/6 mice (4–5 weeks old) were castrated (A, schematic representation of experiments). B–D, 7, 15, 30, 60, and 120 days after castration, levels of iNOS (B), GFAP (C), and CD11b (D) were monitored in the nigra by real-time PCR. E, the level of dopamine was also measured in striatum using Complete Stand-Alone HPLC-ECD System EiCOM HTEC-500. Results are mean ± S.E. (error bars) of five mice per group. a, p < 0.001 versus sham (0 days) control; ns, not significant.

Does Castration of Male Mice at Any Age Induce Nigrostriatal Pathology?
To address this important question, 4–5-week-old, 8–9-week-old, and 13–14-week-old male mice were castrated, and 30 days later the status of TH and glial activation in the nigra and the level of striatal DA were monitored. As mentioned above, castration of 4–5-week-old male mice led to increased expression of GFAP, Iba-1, and iNOS in the nigra compared with sham control (Fig. 7, A and B). Consistently, we also observed decreased expression of nigral TH (Fig. 7, A and B) and loss of striatal DA (Fig. 7C) in 4–5-week-old castrated male mice. In contrast, castration of either 8–9 week-old (Fig. 7, D–F) or 13–14-week-old (Fig. 7, G–I) male mice did not up-regulate nigral glial activation (Fig. 7, D, E, G, and H) compared with respective sham controls. Similarly, castration of 8–9-week-old and 13–14-week-old male mice also did not decrease nigral TH (Fig. 7, D, E, G, and H) and modulate striatal DA (Fig. 7, F and I). These results suggest that castration of male mice at a particular age is important for the induction of nigrostriatal pathology.

Open in a separate window
FIGURE 7.
Castration does not induce glial activation and loss of TH in the SNpc of older male mice. A–J, male C57BL/6 mice (4–5 weeks old (A–C); 8–9 weeks old (D–F); 13–14 weeks old (G–I)) were castrated, and 30 days later, levels of GFAP, Iba-1, iNOS, and TH were monitored in the nigra by Western blotting (A, D, and G). B, E, and H, bands were scanned and are expressed as relative to sham control. C, F, and I, the level of dopamine was also measured in the striatum. Results are mean ± S.E. (error bars) of six mice per group. a, p < 0.001 versus sham-GFAP; b, p < 0.001 versus sham-Iba-1; c, p < 0.001 versus sham-iNOS; d, p < 0.001 versus sham-TH; e, p < 0.001 versus sham-DA. J, concentration of testosterone was assayed in serum of 4–5-week-old, 8–9-week-old, 13–14-week-old, and 16–17-week-old male C57BL/6 mice as described under “Materials and Methods.” Data are means ± S.E. of six mice per group. a, p < 0.01 versus 4–5-week-old mice.

At present, we do not know the correct reason for this particular age requirement. However, in an attempt to find a possible rationale for this interesting observation, we measured the level of testosterone in serum of male mice at different age groups. Decreased serum testosterone levels in 8–9-week-old, 13–14-week-old, and 16–17-week-old male mice compared with 4–5-week-old male mice (Fig. 7J) suggest that 4–5-week-old male mice are probably susceptible to castration-induced nigrostriatal pathology due to the presence of high testosterone level.

Does Testosterone Supplementation Normalize These PD-related Pathologies in Castrated Male Mice?
To find out whether the observed pathological changes are due to castration-related loss of male sex hormone, we performed this experiment. However, testosterone may be converted into estrogen by aromatase. Therefore, to avoid the complexity, castrated male mice received DHT pellets (30-day release), which were implanted subcutaneously in the scapular area of the neck of castrated male mice on the day of castration (Fig. 8A). It is interesting to see that DHT supplementation protected nigral TH (Fig. 8, B and C) and preserved striatal DA (Fig. 8D) in 4–5-week-old castrated male mice. Accordingly, DHT supplementation also improved rotarod performance (Fig. 8E), horizontal activity (Fig. 8F), total distance (Fig. 8G), movement time (Fig. 8H), number of movement (Fig. 8I), and stereotypy (Fig. 8J).

Open in a separate window
FIGURE 8.
Testosterone supplementation normalizes PD-related pathologies and improves locomotor activities in castrated male mice. Male C57BL/6 mice (4–5 weeks old) were castrated, and from the day of castration, 30-day release pellets of DHT (15 mg) as well as placebo pellets were implanted subcutaneously in the scapular area of the neck using a trochar. A is a schematic representation of the experiments. B, after 30 days, the level of TH was monitored in the nigra by Western blotting. C, bands were scanned and expressed as relative to sham control. D, the level of dopamine was quantified in striatum by HPLC. E–J, mice were also tested for motor functions (E, rotarod; F, horizontal activity; G, total distance; H, movement time; I, number of movement; and J, stereotypy counts). Results are mean ± S.E. (error bars) of six mice per group. a, p < 0.01 versus sham; b, p < 0.01 versus castrated.

Castration Is Unable to Induce Nigrostriatal Pathologies in Male iNOS−/− Mice
To understand the mechanism of these unexpected results, we decided to castrate iNOS−/− mice because iNOS is downstream of proinflammatory cytokine signaling and castration induced the expression of iNOS and proinflammatory cytokines in the nigra (Fig. 2). Similar to that observed in male C57BL/6 mice, castration also led to a decrease in TH immunoreactivity in nigra (Fig. 9A) and striatum (Fig. 9B), and loss of TH-positive neurons in the nigra (Fig. 9C) and fibers in the striatum (Fig. 9D) of wild type (C57BL/6J) mice. Western blot analysis of nigral homogenates showed marked loss of TH protein in the nigra of castrated male mice compared with sham male mice (Fig. 9, F and G). Accordingly, castration also decreased striatal DA in male WT mice (Fig. 9E). However, castration remained unable to induce these nigrostriatal pathologies in iNOS−/− male mice (Fig. 9, A–G), indicating that iNOS plays a critical role in castration-induced manifestation of nigrostriatal pathologies in male mice.

Open in a separate window
FIGURE 9.
Castration is unable to induce nigrostriatal pathologies in iNOS−/− male mice. A–E, wild type and iNOS−/− mice (4–5 weeks old) were castrated, and 30 days later, nigral (A) and striatal (B) sections were immunostained with TH followed by stereological counting of nigral TH-positive neurons (C), quantification of striatal TH fibers (D) and assay of striatal dopamine (E). F, nigral homogenates were immunoblotted for TH. G, bands were scanned using ImageJ software (National Institutes of Health) and expressed as relative to control. Results are mean ± S.E. (error bars) of six mice per group. a, p < 0.001 versus sham control; ns, not significant.

Castration Does Not Decrease the Expression of GDNF in the Nigra of Male iNOS−/− Mice
How does iNOS couple to nigrostriatal pathologies? Although iNOS can affect the nigrostriatum via many different ways, we examined whether there was any cross-talk between iNOS and the nigral trophic system. GDNF is a particularly potent factor for survival and axonal growth of mesencephalic dopaminergic neurons (21) and has been shown to ameliorate motor deficits and reduce brain damage in several animal models of PD (22). We tested whether castration was capable of modulating the expression of GDNF in the SNpc of male C57BL/6 mice. One month after castration, we observed a marked decrease in the expression of GDNF mRNA (Fig. 10, A and B) and protein (Fig. 10, C and D) in the SNpc of male mice compared with sham control. Double-label immunofluorescence analysis also revealed that nigral sections of castrated male mice expressed more GFAP and less GDNF than that of sham control (Fig. 10E). Similarly, some neurons also expressed GDNF in the nigra of sham, but not castrated, male mice (Fig. 10F). These results suggest that castration leads to a decrease in the level of GDNF in the SNpc of male mice.

Open in a separate window
FIGURE 10.
Castration decreases the level of GDNF in the SNpc of male mice. A and B, male C57BL/6 mice (4–5 weeks old) were castrated, and 30 days later the mRNA expression of GDNF was examined in the SNpc by semiquantitative RT-PCR (A) and real-time PCR (B). C, the protein level of GDNF was monitored by Western blotting. D, actin was run as loading control. Bands were scanned and expressed as relative to sham control. Results are mean ± S.E. (error bars) of six mice per group. a, p < 0.001 versus sham-control. E and F, GDNF protein was monitored by double-label immunofluorescence with either astrocytes (GFAP) (E) or neurons (NeuN) (F). DAPI was used to visualize nucleus. Results represent analysis of two sections of each of six mice per group.

Because nigral astroglia in normal male mice expressed GDNF, but not iNOS, and nigral astroglia in castrated male mice expressed iNOS, but not GDNF, we examined the role of iNOS in castration-induced loss of GDNF. As observed in C57BL/6 mice, castration of male C57BL/6J mice also led to a marked increase in GFAP and decrease in GDNF protein in the SNpc (Fig. 11,A and B). However, we did not observe any decrease in GDNF or increase in GFAP in iNOS−/− mice after castration (Fig. 11, A and B). Western blot analysis of GDNF also supports this finding (Fig. 11, C and D). Interestingly, the basal level of GDNF was found to be higher in the nigra of iNOS−/− mice than that of WT mice (Fig. 11, A and B). Together, these results suggest that castration leads to a decrease in GDNF in the nigra of male mice via up-regulation of iNOS.

Open in a separate window
FIGURE 11.
Castration is unable to decrease GDNF in the nigra of iNOS−/− male mice. A, wild type and iNOS−/− mice (4–5 weeks old) were castrated, and 30 days after, nigral sections were double-immunolabeled for GFAP and GDNF. B, GDNF-positive cells were counted in an Olympus IX81 fluorescence microscope using the MicroSuite imaging software. C, nigral homogenates were immunoblotted for GDNF. D, bands were scanned using ImageJ software and expressed as relative to control. Results are mean ± S.E. (error bars) of six mice per group. a, p < 0.001 versus sham control.

Does iNOS-derived NO Suppress GDNF?
Next, we examined whether there was any direct cross-talk between NO and GDNF. At first, we performed a time course experiment for GDNF expression and NO production in IL-1β-stimulated primary mouse astrocytes. Although IL-1β initially increased the mRNA expression of GDNF after 6 h of stimulation (Fig. 10A), GDNF mRNA expression gradually vanished with time (Fig. 12A). Interestingly, this expression pattern of GDNF in activated astrocytes was inversely related to NO production (Fig. 12B). To find out whether NO is actually involved in the down-regulation of GDNF, astrocytes were stimulated with IL-1β in the presence or absence of 2-(4-carboxyphenyl)-4,5-dihydro-4,4,5,5-tetramethyl-1H-imidazoyl-1-oxy-3-oxide (PTIO; a NO scavenger) and N6-(1-iminoethyl)-l-lysine (l-NIL; an inhibitor of NOS). After 24 h of stimulation, the mRNA expression of GDNF was monitored by semiquantitative RT-PCR (Fig. 12C), and the protein level (Fig. 12D) of GDNF was assayed by ELISA (Promega). Both PTIO and l-NIL abrogated the inhibitory effect of IL-1β on GDNF, indicating that IL-1β inhibits the expression of GDNF in astrocytes via NO. To prove the role of iNOS in the suppression of GDNF, primary astrocytes isolated from WT and iNOS−/− mice were stimulated with IL-1β followed by analysis of GDNF expression. Interestingly, IL-1β reduced the expression of GDNF protein in WT, but not iNOS−/−, astroglia (Fig. 12, E and F). It was also supported by double-label immunofluoresence of GDNF and GFAP (Fig. 12, G and H), confirming that iNOS-NO signaling plays an important role in the down-regulation of GDNF in activated astroglia.

Open in a separate window
FIGURE 12.
Down-regulation of GDNF in mouse astrocytes by nitric oxide. A and B, primary mouse astrocytes were stimulated with 20 ng/ml IL-1β under serum-free conditions for different time periods followed by monitoring the mRNA expression of IL-1β in cells by semiquantitative RT-PCR (A) and the level of nitrite in supernatants by Griess reagent (B). Results are mean ± S.D. (error bars) of three separate experiments. a, p < 0.001 versus 0 h. C and D, cells were stimulated with IL-1β in the presence or absence of different concentrations of l-NIL and PTIO for 24 h followed by monitoring the mRNA expression of GDNF in cells (C) and the protein level of GDNF in supernatants (D). Results are mean ± S.D. of three separate experiments. a, p < 0.001 versus control; b, p < 0.001 versus IL-1β. E, primary astrocytes isolated from wild type (WT) and iNOS−/− mice were stimulated with IL-1β for 18 h followed by monitoring the level of GDNF protein in cells by Western blotting (E). F, bands were scanned using the ImageJ software. Results are mean ± S.D. of three separate experiments. a, p < 0.001 versus WT-cont. G and H, WT (G) and iNOS−/− (H) astrocytes were stimulated with IL-1β for 24 h followed double-immunolabeling for GFAP and GDNF. Results represent three independent experiments. I, possible hypothesis is shown for castration-induced development of PD-like pathologies.

Go to:
DISCUSSION
Developing a simple, toxin-free and nontransgenic model to study PD-related nigrostriatal pathologies is important because it could assist in easy drug screening. Here, we have successfully demonstrated that simple castration induces PD-related nigrostriatal pathologies in male mice in the absence of any toxins. Our conclusion is based on the following. First, castration led to the loss of dopaminergic neurons in the nigra and fibers in the striatum. This loss was irreversible; even at 4 months after castration, the extent of nigrostriatal damage did not decrease. Second, the DA level markedly decreased 30 days after castration; and even 120 days after castration, we found no improvement in striatal DA level in castrated male mice compared with age-matched normal male mice. Third, castration also led to impairment in locomotor activities, suggesting that castration caused not only structural and neurotransmitter damage but also functional deficits. Because simple castration induced these PD-related nigrostriatal and behavioral changes, our results suggest that some forms of PD (e.g. early onset) in males may be due to a sudden decrease in male sex hormone.

Why did we think of such an unconventional approach? It has been shown that testosterone deficiency is common in the older male population and has an increased prevalence in parkinsonian patients (23, 24). In another study, testosterone therapy led to significant improvement in the resting tremor and fine motor control in parkinsonian patients with testosterone deficiency (25). Testosterone treatment also improved the nonmotor symptoms of PD (26). Finally, TH is also localized to the Leydig cells at both the mRNA and protein levels (27). MPTP intoxication causes marked decrease in serum testosterone level and loss of Leydig cells (28). The loss of Leydig cells is accompanied by a marked decrease in TH protein in the interstitium and significant fall in norepinephrine levels in the testis (28). Therefore, we thought that testosterone could be intimately coupled to the dopaminergic pathway and that castration may induce nigrostriatal pathologies. However, in contrast to our finding, some articles have shown either no effect or an increase in markers of nigrostriatal function (e.g. TH-positive neurons in the SN, striatal dopamine content) following castration (29, 30). In these cases, older mice or rats were used for castration. We also did not observe glial activation or loss in nigral TH and striatal DA 1 month after castration when 8–9-week-old and 13–14-week-old mice were castrated (Fig. 5), indicating that castration induces nigrostriatal pathologies after certain time only when young male mice are castrated probably when testosterone level is maximum (Fig. 7J). Our results may have implications in females as well. Although we have not examined females mice, Rocca et al. (31) have reported increased risk of parkinsonism in women who underwent oophorectomy before menopause. According to this study (31), the risk increased with younger age at oophorectomy. Together, these results suggest that sudden loss of sex hormone in young population may increase the risk of having PD later in life.

How does castration induce nigrostriatal pathologies? Although the disease mechanisms that cause PD are poorly understood, recent studies strongly support a role of inflammation in nigrostriatal degeneration in PD. It has been found that early intervention with nonsteroidal anti-inflammatory drugs slows disease incidence. Furthermore, significant microglial activation occurs in close proximity to damaged or dying dopaminergic neurons. Several studies have shown that iNOS-NO-ONOO− (peroxynitrite) plays important role in the loss of dopaminergic neurons in PD. First, the concentration of NO2− (nitrite), a metabolite of NO, increases in the CSF of patients with PD compared with a group of patients without dopaminergic dysfunction (32). Second, it has been shown that many cells in the SNpc from postmortem PD samples express considerable amounts of iNOS, whereas those from age-matched controls do not (33). Third, iNOS is not only up-regulated in the SNpc of MPTP-treated mice, but its ablation in mutant mice significantly attenuates MPTP neurotoxicity, thus indicating that iNOS is essential in MPTP-induced SNpc dopaminergic neurodegeneration (18). Therefore, we examined the role of iNOS in castration-induced nigrostriatal pathologies in male mice. Interestingly, castration remained unable to induce the loss of nigral TH-positive neurons and striatal TH fibers and the decrease in striatal neurotransmitters in iNOS−/− mice, clearly describing an important role of iNOS in castration-mediated nigrostriatal pathologies.

NO, a short lived and diffusible free radical, plays many roles as a signaling and effector molecule in diverse biological systems; it is a neuronal messenger and is involved in vasodilation as well as in antimicrobial and antitumor activities (34, 35). On the other hand, NO has also been implicated in several CNS disorders, including inflammatory, infectious, traumatic, and degenerative diseases (18, 3638). There is considerable evidence for the transcriptional induction of iNOS (the high output isoform of NOS) in the CNS that is associated with degenerative brain injury (18, 35, 37, 38). NO is potentially toxic to neurons and oligodendrocytes that may mediate toxicity through the formation of iron-NO complexes of iron-containing enzyme systems (39), oxidation of protein sulfhydryl groups (40), nitration of proteins, and nitrosylation of nucleic acids and DNA strand breaks (41). Here, we have described a new mechanism by which iNOS-derived NO may couple nigrostriatal degeneration (summarized in Fig. 12I). Whereas castration increased the expression of iNOS in the nigra, the level of GDNF went down drastically in the nigra after castration. Interestingly, castration remained unable to decrease the expression of GDNF in nigra and striatum in iNOS−/− mice. This also paralleled with the inability of castration of inducing nigrostriatal pathologies in iNOS−/− mice, suggesting that castration causes the loss of dopaminergic neurons in the nigra via iNOS-mediated down-regulation of GDNF (Fig. 12I). GDNF is a particularly potent factor for survival and axonal growth of mesencephalic dopaminergic neurons (21). Kordower et al. (42) used a lentiviral vector to increase GDNF production in the striatum and demonstrated functional and structural recovery when initiating treatment 1 week after a systemic MPTP lesion in monkeys. Although GDNF gene therapy does not work well in PD patients, intraventricular administration of GDNF protein exhibits protection in PD patients (43). Therefore, increasing the levels of these trophic factors and/or maintaining their physiological levels in the CNS of patients with neurodegenerative disorders is/are an important area of research. However, such mechanisms are poorly understood. Here, we demonstrate that NO is a negative regulator of GDNF, suggesting that scavenging of NO may help in restoring and/or increasing the level of GDNF in the degenerative brain.

Go to:
Acknowledgment
We thank Dr. Jeffrey H. Kordower for help in the dihydrotestosterone study.

*This work was supported, in whole or in part, by National Institutes of Health Grants NS64564 and NS71479.

2The abbreviations used are:

PD
Parkinson disease
DA
dopamine
DHT
5α-dihydrotestosterone
DOPAC
3,4-dihydroxyphenylacetic acid
GDNF
glial-derived neuotrophic factor
GFAP
glial fibrillary acidic protein
HVA
homovanillic acid
iNOS
inducible NOS
MPTP
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
SNpc
substantia nigra pars compacta
α-syn
α-synuclein
TH
tyrosine hydroxylase.
Go to:
REFERENCES
1. Olanow C. W., Tatton W. G. (1999) Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 22, 123–144 [PubMed] [Google Scholar]
2. Vila M., Przedborski S. (2004) Genetic clues to the pathogenesis of Parkinson's disease. Nat. Med. 10, S58–62 [PubMed] [Google Scholar]
3. Dauer W., Przedborski S. (2003) Parkinson's disease: mechanisms and models. Neuron 39, 889–909 [PubMed] [Google Scholar]
4. Kurz M. J., Pothakos K., Jamaluddin S., Scott-Pandorf M., Arellano C., Lau Y. S. (2007) A chronic mouse model of Parkinson's disease has a reduced gait pattern certainty. Neurosci. Lett. 429, 39–42 [PMC free article] [PubMed] [Google Scholar]
5. Meredith G. E., Totterdell S., Potashkin J. A., Surmeier D. J. (2008) Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol. Parkinsonism Relat. Disord. 14, S112–115 [PMC free article] [PubMed] [Google Scholar]
6. Tan E. K., Skipper L. M. (2007) Pathogenic mutations in Parkinson disease. Hum. Mutat. 28, 641–653 [PubMed] [Google Scholar]
7. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A., Mucke L. (2000) Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science 287, 1265–1269 [PubMed] [Google Scholar]
8. Maries E., Dass B., Collier T. J., Kordower J. H., Steece-Collier K. (2003) The role of α-synuclein in Parkinson's disease: insights from animal models. Nat. Rev. Neurosci. 4, 727–738 [PubMed] [Google Scholar]
9. Goldberg M. S., Fleming S. M., Palacino J. J., Cepeda C., Lam H. A., Bhatnagar A., Meloni E. G., Wu N., Ackerson L. C., Klapstein G. J., Gajendiran M., Roth B. L., Chesselet M. F., Maidment N. T., Levine M. S., Shen J. (2003) Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J. Biol. Chem. 278, 43628–43635 [PubMed] [Google Scholar]
10. Ghosh A., Corbett G. T., Gonzalez F. J., Pahan K. (2012) Gemfibrozil and fenofibrate, Food and Drug Administration-approved lipid-lowering drugs, up-regulate tripeptidyl-peptidase 1 in brain cells via peroxisome proliferator-activated receptor α: implications for late infantile Batten disease therapy. J. Biol. Chem. 287, 38922–38935 [PMC free article] [PubMed] [Google Scholar]
11. Ghosh A., Pahan K. (2012) Gemfibrozil, a lipid-lowering drug, induces suppressor of cytokine signaling 3 in glial cells: implications for neurodegenerative disorders. J. Biol. Chem. 287, 27189–27203 [PMC free article] [PubMed] [Google Scholar]
12. Khasnavis S., Pahan K. (2012) Sodium benzoate, a metabolite of cinnamon and a food additive, up-regulates neuroprotective Parkinson disease protein DJ-1 in astrocytes and neurons. J. Neuroimmune Pharmacol. 7, 424–435 [PMC free article] [PubMed] [Google Scholar]
13. Ghosh A., Roy A., Matras J., Brahmachari S., Gendelman H. E., Pahan K. (2009) Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease. J. Neurosci. 29, 13543–13556 [PMC free article] [PubMed] [Google Scholar]
14. Roy A., Ghosh A., Jana A., Liu X., Brahmachari S., Gendelman H. E., Pahan K. (2012) Sodium phenylbutyrate controls neuroinflammatory and antioxidant activities and protects dopaminergic neurons in mouse models of Parkinson's disease. PLoS One 7, e38113. [PMC free article] [PubMed] [Google Scholar]
15. Roy A., Pahan K. (2011) Prospects of statins in Parkinson disease. Neuroscientist 17, 244–255 [PMC free article] [PubMed] [Google Scholar]
16. Mondal S., Roy A., Jana A., Ghosh S., Kordower J. H., Pahan K. (2012) Testing NF-κB-based therapy in hemiparkinsonian monkeys. J. Neuroimmune Pharmacol. 7, 544–556 [PMC free article] [PubMed] [Google Scholar]
17. Ghosh A., Roy A., Liu X., Kordower J. H., Mufson E. J., Hartley D. M., Ghosh S., Mosley R. L., Gendelman H. E., Pahan K. (2007) Selective inhibition of NF-κB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 104, 18754–18759 [PMC free article] [PubMed] [Google Scholar]
18. Liberatore G. T., Jackson-Lewis V., Vukosavic S., Mandir A. S., Vila M., McAuliffe W. G., Dawson V. L., Dawson T. M., Przedborski S. (1999) Inducible nitric-oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 5, 1403–1409 [PubMed] [Google Scholar]
19. Wu D. C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D. K., Ischiropoulos H., Przedborski S. (2002) Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22, 1763–1771 [PMC free article] [PubMed] [Google Scholar]
20. González-Scarano F., Baltuch G. (1999) Microglia as mediators of inflammatory and degenerative diseases. Annu. Rev. Neurosci. 22, 219–240 [PubMed] [Google Scholar]
21. Burke R. E. (2006) GDNF as a candidate striatal target-derived neurotrophic factor for the development of substantia nigra dopamine neurons. J. Neural Transm. Suppl. 70, 41–45 [PubMed] [Google Scholar]
22. Dietz G. P., Valbuena P. C., Dietz B., Meuer K., Müeller P., Weishaupt J. H., Bähr M. (2006) Application of a blood-brain-barrier-penetrating form of GDNF in a mouse model for Parkinson's disease. Brain Res. 1082, 61–66 [PubMed] [Google Scholar]
23. Kenangil G., Orken D. N., Ur E., Forta H., Celik M. (2009) The relation of testosterone levels with fatigue and apathy in Parkinson's disease. Clin. Neurol. Neurosurg. 111, 412–414 [PubMed] [Google Scholar]
24. Okun M. S., Crucian G. P., Fischer L., Walter B. L., Testa C. M., Vitek J. L., DeLong M. R., Hanfelt J., Huang X. (2004) Testosterone deficiency in a Parkinson's disease clinic: results of a survey. J. Neurol. Neurosurg. Psychiatry 75, 165–166 [PMC free article] [PubMed] [Google Scholar]
25. Mitchell E., Thomas D., Burnet R. (2006) Testosterone improves motor function in Parkinson's disease. J. Clin. Neurosci. 13, 133–136 [PubMed] [Google Scholar]
26. Okun M. S., Walter B. L., McDonald W. M., Tenover J. L., Green J., Juncos J. L., DeLong M. R. (2002) Beneficial effects of testosterone replacement for the nonmotor symptoms of Parkinson disease. Arch. Neurol. 59, 1750–1753 [PubMed] [Google Scholar]
27. Davidoff M. S., Ungefroren H., Middendorff R., Koeva Y., Bakalska M., Atanassova N., Holstein A. F., Jezek D., Pusch W., Müller D. (2005) Catecholamine-synthesizing enzymes in the adult and prenatal human testis. Histochem. Cell Biol. 124, 313–323 [PubMed] [Google Scholar]
28. Ruffoli R., Giambelluca M. A., Scavuzzo M. C., Pasquali L., Giannessi F., Fornai F. (2008) MPTP-induced parkinsonism is associated with damage to Leydig cells and testosterone loss. Brain Res. 1229, 218–223 [PubMed] [Google Scholar]
29. Dluzen D. E., Ramirez V. D. (1989) Effects of orchidectomy on nigro-striatal dopaminergic function: behavioral and physiological evidence. J. Neuroendocrinol. 1, 285–290 [PubMed] [Google Scholar]
30. Tamás A., Lubics A., Lengvári I., Reglodi D. (2006) Effects of age, gender, and gonadectomy on neurochemistry and behavior in animal models of Parkinson's disease. Endocrine 29, 275–287 [PubMed] [Google Scholar]
31. Rocca W. A., Bower J. H., Maraganore D. M., Ahlskog J. E., Grossardt B. R., de Andrade M., Melton L. J., 3rd (2008) Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology 70, 200–209 [PubMed] [Google Scholar]
32. Qureshi G. A., Baig S., Bednar I., Södersten P., Forsberg G., Siden A. (1995) Increased cerebrospinal fluid concentration of nitrite in Parkinson's disease. Neuroreport 6, 1642–1644 [PubMed] [Google Scholar]
33. Hunot S., Boissière F., Faucheux B., Brugg B., Mouatt-Prigent A., Agid Y., Hirsch E. C. (1996) Nitric-oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 72, 355–363 [PubMed] [Google Scholar]
34. Nathan C. (1992) Nitric oxide as a secretory product of mammalian cells. FASEB J. 6, 3051–3064 [PubMed] [Google Scholar]
35. Saha R. N., Pahan K. (2006) Regulation of inducible nitric-oxide synthase gene in glial cells. Antioxid. Redox Signal. 8, 929–947 [PMC free article] [PubMed] [Google Scholar]
36. Akama K. T., Albanese C., Pestell R. G., Van Eldik L. J. (1998) Amyloid β-peptide stimulates nitric oxide production in astrocytes through an NFκB-dependent mechanism. Proc. Natl. Acad. Sci. U.S.A. 95, 5795–5800 [PMC free article] [PubMed] [Google Scholar]
37. Merrill J. E., Ignarro L. J., Sherman M. P., Melinek J., Lane T. E. (1993) Microglial cell cytotoxicity of oligodendrocytes is mediated through nitric oxide. J. Immunol. 151, 2132–2141 [PubMed] [Google Scholar]
38. Liu X., Jana M., Dasgupta S., Koka S., He J., Wood C., Pahan K. (2002) Human immunodeficiency virus type 1 (HIV-1) tat induces nitric-oxide synthase in human astroglia. J. Biol. Chem. 277, 39312–39319 [PMC free article] [PubMed] [Google Scholar]
39. Drapier J. C., Hibbs J. B., Jr. (1988) Differentiation of murine macrophages to express nonspecific cytotoxicity for tumor cells results in l-arginine-dependent inhibition of mitochondrial iron-sulfur enzymes in the macrophage effector cells. J. Immunol. 140, 2829–2838 [PubMed] [Google Scholar]
40. Radi R., Beckman J. S., Bush K. M., Freeman B. A. (1991) Peroxynitrite oxidation of sulfhydryls: the cytotoxic potential of superoxide and nitric oxide. J. Biol. Chem. 266, 4244–4250 [PubMed] [Google Scholar]
41. Wink D. A., Kasprzak K. S., Maragos C. M., Elespuru R. K., Misra M., Dunams T. M., Cebula T. A., Koch W. H., Andrews A. W., Allen J. S. (1991) DNA deaminating ability and genotoxicity of nitric oxide and its progenitors. Science 254, 1001–1003 [PubMed] [Google Scholar]
42. Kordower J. H., Emborg M. E., Bloch J., Ma S. Y., Chu Y., Leventhal L., McBride J., Chen E. Y., Palfi S., Roitberg B. Z., Brown W. D., Holden J. E., Pyzalski R., Taylor M. D., Carvey P., Ling Z., Trono D., Hantraye P., Déglon N., Aebischer P. (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290, 767–773 [PubMed] [Google Scholar]
43. Hoffer B. J., Harvey B. K. (2011) Is GDNF beneficial in Parkinson disease? Nat. Rev. Neurol. 7, 600–602 [PMC free article] [PubMed] [Google Scholar]
 

S-VV

Member
Joined
Jul 23, 2018
Messages
457
This will never catch on as a model, because a therapeutic intervention is immediate and trivial following this model: androgens, which are a big no-no for modern medicine. Im sure they will find a way to spin it as an oestrogen deficiency
 
Similar threads
Thread starter Title Forum Replies Date
G My high estrogen won't drop. Help Ask For Help or Advice 27
theantagonist How much ml in one drop, idealabs bottle dropper? IdeaLabs 5
haidut Drop In Mom's Thyroid Levels, Undetectable By Blood Tests, Tanks Child IQ Scientific Studies 1
D Big Drop In Body Temperature While Walking Thyroid and Hormones 9
yerrag Drop All Charges Against Assange, Trump! Political Talk, Alternative World Theories 6
N Low Cortisol At Night Causing Drop In Sugar -- Waking Up Frequently Blood Sugar 12
Deadpool 1 Drop Of Thyroid Gave Me A Panic Attack? Ask For Help or Advice 38
Such_Umami Visceral Fat Drop Strategy Ask For Help or Advice 0
LucyL No. 1 Milk Company Declares Bankruptcy Amid Drop In Demand Miscellaneous Health Discussions 25
L Thorne Research - Vitamin K2 Liquid (1 Mg/drop) - 30 Ml (Dosage, Expiration, Storage) K 7
D Suggestions For Dealing With Sudden Temperature Drop Metabolism 4
Drareg Sperm Count Drop 'may Lead To Human Extinction' Political Talk, Alternative World Theories 53
cyclops Why Do Women's Progesterone Levels Drop After Giving Birth? Female Issues 15
N Temperature Drop After Exercise Metabolism 7
nikkmm Significant Pulse Drop At Night Combined With Major Anxiety And Breathlessness. Any Ideas? Ask For Help or Advice 16
haidut Pregnenolone, Progesterone And DHEA Drop, Cortisol Rises In Aging Scientific Studies 29
S Liquid Supplement Drop Size Supplements, Pharmaceutical Drugs 0
haidut Despite 10% Drop In Caloric Intake, Childhood Obesity On The Rise In The USA Scientific Studies 5
S Are You Interested In A Retinol Supplement With 15,000 IU Per Drop? Health Natura 19
SarahBeara Stressors drop skin temperature in hens Articles & Scientific Studies 0
bornamachine Vitamin E Caused Temperature Drop. E 13
haidut Significant drop in mortality when doctors are away from work Scientific Studies 5
R Progest-E: Dosage, Drop Size Progesterone 8
charlie Mexican Coke Faces Extinction, May Drop Cane Sugar for HFCS Soda (Mexican Coke, Pepsi, etc.) 20
4peatssake "Even on the mornings that you don't drop dead... Ray Peat Quotes 2
BingDing Potato egg drop soup Recipes 3
S What caused a major drop in T levels and metabolism Ask For Help or Advice 0
Zsazsa Hormone drugs that reduce androgen levels may help disarm the coronavirus spike protein Scientific Studies 0
TheBeard Fetal androgen exposure is a determinant of adult male metabolic health Thyroid and Hormones 3
Hgreen56 High sugar consumption could cause the body to become unable to regulate androgen levels? Hormones 21
D Is Beard Growth Androgen, Estrogen, or Nitric Oxide related? Or all the above? Male Issues 30
5 Chronic, High-Dose Androgen Use and Adrenal Suppression Male Issues 0
Mito Early decline of androgen levels in healthy adult men: an effect of aging per se? Scientific Studies 1
johnwester130 Anti-Peat DHEA is an anti-androgen Debate - Anti-Peat 8
Spartan300 Low Androgen Symptoms - Tests Ok - Time To Rethink Male Issues 33
haidut Dietary PUFA Causes (reversible) Male Infertility And Androgen Deficiency Scientific Studies 4
S DHT And Reversing Androgen-receptor Deficiency Ask For Help or Advice 17
J CPT1 And Androgen Receptor Male Issues 0
Lokzo Estrogen Up-regulates Androgen Receptors (AR) In The Brain Scientific Studies 5
Lokzo Inhibition Of Androgen Receptor Can Decrease Fat Metabolism In Skeletal Muscles Of Trained Mice Scientific Studies 0
Hans What Androgen Related Symptoms Do You Suffer From? Polls 6
R The Gut Microbiota Is A Major Regulator Of Androgen Metabolism In Intestinal Contents Scientific Studies 1
W ANDROGEN BLOCKERS Male Issues 0
L 2 Recent Studies On Cortisol/androgen Relationship Scientific Studies 0
L The Anabolic Potencies Of Different Androgen Hormones? Thyroid and Hormones 3
Cameron Forskolin Estrogenic Or Powerful Androgen Booster Through Camp? Supplements, Pharmaceutical Drugs 1
jase_11six How To Increase Androgen Receptors In My Cheek ? Hair & Nails 133
Cameron Low Dose (3-5mg) Test And Dht Topical For Massive Androgen Increase Male Issues 54
Lokzo Serotonin Regulates Prostate Growth Through Androgen Receptor Modulation Scientific Studies 3
Sajid Androgen Receptor Sensitivity Ask For Help or Advice 2

Similar threads

Top